New Analyses of PSC Data from Phase 2 SPRING Trial Show that Treatment with Nebokitug Is Associated with Dose-Dependent and Significant Improvements in Multiple Inflammatory and Fibrotic Biomarkers Fu ...

The global primary sclerosing cholangitis (PSC) market is on an impressive growth trajectory, with forecasts estimating a market valuation of USD 314.26 million by 2033. This robust expansion is ...

Ipsen Biopharmaceuticals Canada Inc. today announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) ...

Most people have never heard of primary biliary cholangitis (PBC), but the progressive, rare cholestatic liver disease can ...

Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic and progressive disease that damages and can eventually destroy the bile ducts of the liver. Researchers ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that ...

Livdelzi is now FDA-approved for treating the rare liver disease primary biliary cholangitis. Gilead Sciences added the drug to its pipeline via the $4.3 billion acquisition of CymaBay ...

Primary biliary cholangitis (PBC) is an autoimmune disorder that leads to the destruction of bile ducts within the liver. As more bile ducts become lost and damaged, bile acids build up within the ...

New Jersey Rep. Donald Norcross is in intensive care​ after he was diagnosed with cholangitis, a gallbladder infection that ...

Rep. Donald Norcross (D-N.J.) has been transferred out of an intensive care unit (ICU), according to a Tuesday press release ...

A copy of the R&D Day presentation can be found here. About Primary Sclerosing Cholangitis Primary Sclerosing Cholangitis (PSC) is a rare, progressive, cholestatic, immune‐mediated disease of ...

Esperion announced the expansion of its development portfolio with a new program aimed at treating primary sclerosing cholangitis (PSC), a rare liver disease. The company confirmed the ...